Cocrystal Pharma Current Ratio 2008-2021 | COCP

Cocrystal Pharma current ratio from 2008 to 2021. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations.
Cocrystal Pharma Current Ratio Historical Data
Date Current Assets Current Liabilities Current Ratio
2021-06-30 $0.07B $0.00B 28.31
2021-03-31 $0.03B $0.00B 23.12
2020-12-31 $0.03B $0.00B 25.05
2020-09-30 $0.03B $0.00B 12.59
2020-06-30 $0.02B $0.00B 6.83
2020-03-31 $0.02B $0.00B 11.73
2019-12-31 $0.01B $0.00B 3.62
2019-09-30 $0.01B $0.00B 3.33
2019-06-30 $0.01B $0.00B 4.60
2019-03-31 $0.01B $0.00B 5.63
2018-12-31 $0.00B $0.00B 1.89
2018-09-30 $0.01B $0.00B 4.39
2018-06-30 $0.01B $0.00B 6.74
2018-03-31 $0.00B $0.00B 1.09
2017-12-31 $0.00B $0.00B 1.51
2017-09-30 $0.00B $0.00B 1.64
2017-06-30 $0.01B $0.00B 2.75
2017-03-31 $0.00B $0.00B 1.53
2016-12-31 $0.01B $0.00B 2.68
2016-09-30 $0.01B $0.00B 2.14
2016-06-30 $0.01B $0.00B 1.76
2016-03-31 $0.01B $0.01B 1.85
2015-12-31 $0.01B $0.01B 1.48
2015-09-30 $0.01B $0.00B 3.19
2015-06-30 $0.02B $0.01B 2.22
2015-03-31 $0.02B $0.02B 1.08
2014-12-31 $0.01B $0.01B 0.70
2014-09-30 $0.01B $0.01B 0.76
2014-06-30 $0.01B $0.01B 1.46
2014-03-31 $0.01B $0.01B 0.80
2013-12-31 $0.00B $0.00B 3.04
2013-09-30 $0.00B $0.02B 0.19
2013-06-30 $0.00B $0.01B 0.32
2013-03-31 $0.00B $0.01B 0.27
2012-12-31 $0.01B $0.01B 0.62
2012-09-30 $0.00B $0.01B 0.67
2012-06-30 $0.00B $0.01B 0.44
2012-03-31 $0.00B $0.01B 0.30
2011-12-31 $0.00B $0.01B 0.40
2011-09-30 $0.01B $0.01B 0.78
2011-06-30 $0.01B $0.01B 0.85
2011-03-31 $0.00B $0.00B 0.91
2010-12-31 $0.00B $0.01B 0.83
2010-09-30 $0.00B $0.00B 0.32
2010-06-30 $0.00B $0.00B 0.44
2010-03-31 $0.00B $0.00B 0.71
2009-12-31 $0.00B $0.00B 0.79
2009-09-30 $0.00B $0.00B 0.96
2009-06-30 $0.00B $0.00B 1.09
2009-03-31 $0.00B $0.00B 1.35
2008-12-31 $0.00B $0.00B 1.79
2008-09-30 $0.00B $0.00B 2.08
2008-06-30 $0.00B $0.00B 2.40
2008-03-31 $0.00B 0.00
2007-09-30 $0.00B 0.00
2007-06-30 $0.00B 0.00
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.093B $0.002B
Cocrystal Pharma, Inc. is a clinical stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of hepatitis viruses, influenza viruses, and noroviruses. Cocrystal employs unique structure-based technologies and Nobel Prize winning expertise to create first- and best-in-class antiviral drugs. CC-31244 is a Phase 2a ready broad-spectrum novel non-nucleoside replication inhibitor of HepC. Phase 1b studies in HepC infected patients showed the largest reduction in viral load of any non-nucleoside inhibitor tested to date. The next step for CC-31244 is clinical trials as part of a cocktail for ultra-short therapy of 2 to 6 weeks. The lead candidate for influenza has advanced to IND-enabling studies. It is effective in animal models against both the pandemic and seasonal strains of influenza. In addition, the Company has a pipeline of promising early preclinical programs. Two private investors own approximately 48% of the Company.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $127.994B 8.52
Bio-Rad Laboratories (BIO.B) United States $21.730B 46.31
QIAGEN (QGEN) Netherlands $12.309B 20.85
Biohaven Pharmaceutical Holding (BHVN) United States $9.150B 0.00
Emergent Biosolutions (EBS) United States $2.677B 6.46
Arcus Biosciences (RCUS) United States $2.522B 0.00
Myovant Sciences (MYOV) United Kingdom $1.905B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.799B 0.00
Zymeworks (ZYME) Canada $1.071B 0.00
Ambrx Biopharma (AMAM) United States $0.474B 0.00
SQZ Biotechnologies (SQZ) United States $0.341B 0.00
Enzo Biochem (ENZ) United States $0.160B 15.76